CBDV study for Prader-Willi syndrome halted early
NCT ID NCT03848481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center, Albert Einstein College of Medicine
The Bronx, New York, 10467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early parent coaching help infants with rare genetic disorders thrive?
- Newborn screening study aims to catch rare diseases at birth
- Brain and eye clues to emotion recognition in autism and psychosis
- New group therapy aims to tame meltdowns in Prader-Willi teens
- Can a light box beat daytime sleepiness in Prader-Willi?
- Hormone study aims to unlock Prader-Willi feeding mystery